Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Rituximab
MabThera
Routinely available
NICE (TA243 (SMC 493/08))
02/03/2011
Indication
For the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
100mg and 500mg concentrate for solution for infusion
Comments
March 2011 - Added to the Additional List, for Specialist Use only. January 2012 - NICE MTA advice: SMC advice 493/08 is superseded by NICE TA243.
Link to Advice
Advice Published
25/01/2012